WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year
Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,.
Ionis Pharmaceuticals, Inc. announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 in Angelman syndrome. ION582 was.
Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part.
/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the.
Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the study Encouraging EEG and clinical observations support continued development MIAMI, Nov. 11, 2023 /PRNewswire/ — Ionis Pharmaceuticals, […]